A Phase 1 interventional study of Sym023 in Metastatic Cancer, Solid Tumor and Lymphoma, sponsored by Symphogen A/S. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-12.
Sponsored by Symphogen A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.
Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 1,282nd largest by enrollment of the 1,866 interventional ones that give a count, is one of 74 that started in 2018, is one of 710 in phase 1, and was the 1,238th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
SystImmune Inc. · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,057 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 978 · Phase 2 855 · Phase 3 186 · Phase 4 15
First in 1978; this study’s year is marked. 74 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 43 across the 1,866 interventional studies, 100 across the 139 observational. Of the 1,391 that completed or were terminated, 602 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
927 of 2,057 have an industry lead sponsor. The 10 most frequent:
Symphogen A/S is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
Symphogen A/S has 5 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
202 of the studies in Neoplasm Metastasis with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03525873Phase 3M.D. Anderson Cancer CenterA Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy | 2026-12-31 |
| NCT03927885Phase 3M.D. Anderson Cancer CenterOpen Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer | 2026-12-31 |
| NCT06947928Phase 3TuHURA Biosciences, Inc.Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | 2027-03-31 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 202 to your calendar (.ics) → With an account.
Among the 2,057 studies in Neoplasm Metastasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was the first study to test Sym023 in humans. The primary purpose of this study was to see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
This study evaluated the preliminary safety, tolerability, and dose-limiting toxicities (DLTs) of Sym023, a recombinant, fully human, anti-T-cell immunoglobulin and mucin-domain containing-3 (anti-TIM-3) monoclonal antibody (mAb). The goal was to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of Sym023 when administered once every 2 weeks (Q2W) by intravenous (IV) infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available. If an MTD was not identified, a maximum administered dose (MAD) was to be determined. Sym023 was given to patients in escalating dose cohorts; each patient was given one fixed dose level.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sym023 was administered at a dose of 0.03 mg/kg by intravenous infusion
Drug: Sym023
Sym023 was administered at a dose of 0.1 mg/kg by intravenous infusion
Drug: Sym023
Sym023 was administered at a dose of 0.3 mg/kg by intravenous infusion
Drug: Sym023
Sym023 was administered at a dose of 1.0 mg/kg by intravenous infusion
Drug: Sym023
Sym023 was administered at a dose of 3.0 mg/kg by intravenous infusion
Drug: Sym023
Sym023 was administered at a dose of 10.0 mg/kg by intravenous infusion
Drug: Sym023
Sym023 was administered at a dose of 20.0 mg/kg by intravenous infusion
Drug: Sym023
Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
Also known as: Anti-TIM-3
Assessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria.
Assess the safety and tolerability of Sym023 on a Q2W (once every 2 weeks) schedule to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1. The MTD was to be determined by those DLTs that occurred during C1 in either more than 1 patient in a 3 to 6 patient cohort or ≥33.3% of patients in the event of an expanded 7 to 12 patient cohort. One patient in the 10.0 mg/kg dose cohort was not evaluable for MTD as she did not complete C1 for a reason other than drug toxicity (i.e., discontinuation after 1 dose due to patient withdrawal of consent). However, this patient was included in the evaluation of other outcomes.
Time frame: 28 days
Evaluation of the Immunogenicity of Sym023.
Serum sampling to assess the potential for anti-drug antibody (ADA) formation. The number of patients with positive samples at indicated visits is presented.
Time frame: Baseline up to 6-months follow-up, approximately 1 year
Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIST v1.1
OR or SD Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.
Time frame: 24 months
Evaluation of Objective Response (OR) or Stable Disease (SD) by iRECIST
OR or SD Assessed by Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.
Time frame: 24 months
Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIL 2017.
OR or SD Assessed by Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017)
Time frame: 24 months
Time to Progression (TTP) of Disease.
Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type. The numbers shown below correspond to the values related to RECIST v1.1.
Time frame: 24 months
Area Under the Concentration-time Curve in a Dosing Interval (AUC).
The AUC after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
Time frame: From before the start of the infusion to 168 hours after the end of the infusion
Maximum Concentration (Cmax)
Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
Time frame: From before the start of the infusion to 168 hours after the end of the infusion
Time to Reach Maximum Concentration (Tmax)
Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
Time frame: From before the start of the infusion to 168 hours after the end of the infusion
Trough Concentration (Ctrough)
Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
Time frame: From before the start of the infusion to 168 hours after the end of the infusion
Terminal Elimination Half-life (T½)
Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
Time frame: From before the start of the infusion to 168 hours after the end of the infusion
Clearance (CL)
Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
Time frame: From before the start of the infusion to 168 hours after the end of the infusion
| Milestone | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 3 | 3 | 3 | 7 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 3 | 3 | 3 | 7 | 6 |
| Withdrew: Documented progressive disease | 1 | 0 | 3 | 1 | 3 | 5 | 4 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Clinical progression | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
Assess the safety and tolerability of Sym023 on a Q2W (once every 2 weeks) schedule to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1. The MTD was to be determined by those DLTs that occurred during C1 in either more than 1 patient in a 3 to 6 patient cohort or ≥33.3% of patients in the event of an expanded 7 to 12 patient cohort. One patient in the 10.0 mg/kg dose cohort was not evaluable for MTD as she did not complete C1 for a reason other than drug toxicity (i.e., discontinuation after 1 dose due to patient withdrawal of consent). However, this patient was included in the evaluation of other outcomes.
| Number of DLTs | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Assessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria. | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Serum sampling to assess the potential for anti-drug antibody (ADA) formation. The number of patients with positive samples at indicated visits is presented.
| Participants | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Cycle 1 days 1 and 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cycle 2 day 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cycle 3 days 1 and 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cycle 4 days 1 and 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cycle 5 day 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Cycle 6 day 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cycle 7 day 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| End of treatment | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| 1-month follow up | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| 3-month follow up | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
OR or SD Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.
| Participants | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| OR rate | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SD >16 weeks | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| SD ≤16 weeks | 0 | 0 | 0 | 2 | 2 | 0 | 3 |
OR or SD Assessed by Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.
| Participants | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| OR rate | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| iSD >16 weeks | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
| iSD ≤16 weeks | 0 | 0 | 0 | 2 | 1 | 0 | 4 |
OR or SD Assessed by Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017)
No measurements were reported for this outcome.
Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type. The numbers shown below correspond to the values related to RECIST v1.1.
| months | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Time to Progression (TTP) of Disease. | 1.81 (1.81 to 1.81) | 7.89 (7.89 to 7.89) | 1.18 (0.72 to 1.38) | 3.48 (1.87 to 3.55) | 1.28 (1.12 to 3.52) | 1.68 (0.03 to 2.07) | 5.36 (1.61 to 5.55) |
The AUC after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
| h*μg/mL | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve in a Dosing Interval (AUC). | 70 (70 to 70) | 176 (176 to 176) | 878 (680 to 1158) | 3193 (2449 to 4194) | 8062 (4498 to 12358) | 30581 (7039 to 45928) | 77262 (54275 to 85463) |
Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
| μg/mL | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Maximum Concentration (Cmax) | 0.85 (0.85 to 0.85) | 1.98 (1.98 to 1.98) | 7.94 (5.67 to 11.56) | 23.71 (19.87 to 28.30) | 68.03 (52.88 to 84.16) | 232.11 (183.26 to 288.01) | 470.24 (294.82 to 543.46) |
Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
| hours | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Time to Reach Maximum Concentration (Tmax) | 4.5 (4.5 to 4.5) | 0.6 (0.6 to 0.6) | 1.2 (0.5 to 2.5) | 4.5 (4.4 to 4.7) | 1.8 (0.6 to 2.6) | 3.4 (0.5 to 8.5) | 7.3 (0.5 to 20.8) |
Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
| μg/mL | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Trough Concentration (Ctrough) | NA (NA to NA) | 0.16 (0.16 to 0.16) | 1.26 (0.76 to 1.85) | 6.39 (4.26 to 9.37) | 12.88 (4.09 to 26.10) | 74.33 (37.47 to 116.52) | 146.96 (101.68 to 189.29) |
Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
| hours | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Terminal Elimination Half-life (T½) | NA | 105.10 (105.10 to 105.10) | 153.49 (136.70 to 164.11) | — | 140.60 (112.78 to 168.42) | 185.22 (153.43 to 217.01) | 203.07 (203.07 to 203.07) |
Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.
| mL/h)/kg | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Clearance (CL) | — | 0.501 (0.501 to 0.501) | 0.364 (0.364 to 0.364) | — | 0.582 (0.582 to 0.582) | — | — |
Collected over 24 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sym023 0.03 mg/kg | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Sym023 0.1 mg/kg | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Sym023 0.3 mg/kg | 3/3 (100%) | 0/3 (0%) | 3/3 (100%) |
| Sym023 1.0 mg/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Sym023 3.0 mg/kg | 2/3 (66.7%) | 0/3 (0%) | 3/3 (100%) |
| Sym023 10.0 mg/kg | 1/7 (14.3%) | 2/7 (28.6%) | 7/7 (100%) |
| Sym023 20.0 mg/kg | 1/6 (16.7%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Event | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Immune-mediated arthritisMusculoskeletal and connective tissue disorders | 0/1 | 1/1 | 0/3 | 0/3 | 0/3 | 0/7 | 0/6 |
| Back painMusculoskeletal and connective tissue disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/7 | 1/6 |
| Spinal cord compressionNervous system disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 0/7 | 1/6 |
| Pathological fractureMusculoskeletal and connective tissue disorders | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 1/7 | 0/6 |
| Lipase increasedInvestigations | 0/1 | 0/1 | 0/3 | 0/3 | 0/3 | 1/7 | 0/6 |
| Event | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 1/1 | 1/1 | 2/3 | 1/3 | 1/3 | 2/7 | 1/6 |
| Lymphocyte count decreasedInvestigations | 1/1 | 0/1 | 0/3 | 0/3 | 0/3 | 1/7 | 0/6 |
| AnemiaBlood and lymphatic system disorders | 0/1 | 0/1 | 1/3 | 0/3 | 1/3 | 1/7 | 2/6 |
| ConstipationGastrointestinal disorders | 0/1 | 0/1 | 0/3 | 1/3 | 0/3 | 1/7 | 1/6 |
| NauseaGastrointestinal disorders | 0/1 | 0/1 | 1/3 | 0/3 | 1/3 | 0/7 | 1/6 |
| PyrexiaGastrointestinal disorders | 0/1 | 0/1 | 0/3 | 0/3 | 1/3 | 1/7 | 0/6 |
| HyperbilirubinemiaHepatobiliary disorders | 0/1 | 0/1 | 1/3 | 1/3 | 0/3 | 0/7 | 0/6 |
| Urinary tract infectionInfections and infestations | 0/1 | 0/1 | 0/3 | 1/3 | 1/3 | 0/7 | 1/6 |
| PneumoniaInfections and infestations | 0/1 | 0/1 | 1/3 | 0/3 | 0/3 | 1/7 | 0/6 |
| HypophosphatemiaMetabolism and nutrition disorders | 0/1 | 0/1 | 1/3 | 1/3 | 0/3 | 1/7 | 1/6 |
The full analysis set (FAS) comprised all consented patients who had received at least a fraction of 1 dose of study drug. The patients in the FAS contributed to the analyses as allocated to treatment.
| Age, Categorical(Participants) | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 1 | 2 | 1 | 1 | 5 | 5 | 16 |
| >=65 years | 0 | 0 | 1 | 2 | 2 | 2 | 1 | 8 |
| Age, Continuous(years) | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Median | 64 (64 to 64) | 64 (64 to 64) | 62 (59 to 67) | 66 (45 to 70) | 71 (59 to 72) | 54 (37 to 76) | 61 (36 to 74) | 63 (36 to 76) |
| Sex: Female, Male(Participants) | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 2 | 2 | 3 | 4 | 4 | 16 |
| Male | 1 | 0 | 1 | 1 | 0 | 3 | 2 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 1 | 3 | 3 | 2 | 7 | 6 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 |
| White | 1 | 1 | 3 | 3 | 2 | 2 | 5 | 17 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Canada | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 5 |
| United States | 1 | 1 | 3 | 2 | 2 | 5 | 5 | 19 |
| ECOG PS(Participants) | Sym023 0.03 mg/kg | Sym023 0.1 mg/kg | Sym023 0.3 mg/kg | Sym023 1.0 mg/kg | Sym023 3.0 mg/kg | Sym023 10.0 mg/kg | Sym023 20.0 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | 2 | 2 | 3 | 6 | 4 | 19 |
| 0 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2018 to primary completion in Jun 2020, 24 months.
Results were first posted in Oct 2021, 1 year 4 months after primary completion.
Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 24 months is below that.
Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SYM-023
Symphogen A/S